Byonyks medical devices Headquarters & Office Locations

Byonyks medical devices (Private) is headquartered in Itasca, Illinois, United States. Founded in 2019, the company operates across 1 countries with approximately 93 employees worldwide.

Where is Byonyks medical devices's main office?

Byonyks medical devices's main headquarters office is located at 550 East Devon Ave Itasca Il Suite 140, Itasca, Illinois 60143. This serves as the company's primary corporate address and is home to its executive leadership team.

Byonyks medical devices regional offices

Beyond its headquarters in Itasca, Byonyks medical devices maintains 2 offices across 1 countries. Regional offices span 1 countries.

Byonyks medical devices contact information

The main switchboard for Byonyks medical devices headquarters can be reached at 872-243-6146. For investor relations, visit byonyks.com/investor-relations.

What does Byonyks medical devices do?

Byonyks has pioneered the world’s first affordable Bloodless Dialysis machine, transforming care for kidney failure patients. Globally, over eight million people with kidney disease lack dialysis access-a costly, invasive, and time-consuming treatment that filters blood when kidneys fail. Many of these individuals face life-threatening consequences due to the lack of proper care. Byonyks addresses this critical issue with its Bloodless Dialysis machine; a safe, effective, portable, and non-invasive solution that’s more affordable than existing options. Our technology empowers patients to perform dialysis at home, overnight, while they sleep, allowing them to maintain their daily work and family responsibilities. The needle-free approach also reduces the risk of chronic infections such as HIV and Hepatitis C. Headquartered in the USA and South Asia, Byonyks is a medical device startup founded by Harvard/MIT graduates and industry experts. Our core team’s expertise contributes to over half of the operational peritoneal dialysis machines worldwide. The groundbreaking Bloodless Dialysis machine has saved multiple lives in South Asia and is currently under FDA review-a pivotal step towards making accessible kidney care a global reality.